Clinical trials
Recurrence trials in Denmark
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
94 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 9 |
| 2008 | 2 |
| 2009 | 2 |
| 2010 | 3 |
| 2011 | 4 |
| 2012 | 4 |
| 2013 | 1 |
| 2014 | 7 |
| 2015 | 7 |
| 2016 | 4 |
| 2017 | 6 |
| 2018 | 6 |
| 2019 | 7 |
| 2020 | 3 |
| 2021 | 3 |
| 2022 | 3 |
| 2023 | 7 |
| 2024 | 5 |
| 2025 | 9 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 43 |
| Recruiting | 16 |
| Active, not recruiting | 15 |
| Terminated | 11 |
| Unknown status | 8 |
| Enrolling by invitation | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Celgene | 8 |
| University of Aarhus | 6 |
| Novartis Pharmaceuticals | 5 |
| Zealand University Hospital | 5 |
| AstraZeneca | 4 |
| Genmab | 4 |
| Princess Maxima Center for Pediatric Oncology | 4 |
| Aarhus University Hospital | 3 |
| Alexion Pharmaceuticals, Inc. | 3 |
| Amgen | 3 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Recurrence | 94 |
| Multiple Myeloma | 19 |
| Neoplasms | 9 |
| Lymphoma, Non-Hodgkin | 7 |
| Lymphoma, Follicular | 5 |
| Lymphoma, Large B-Cell, Diffuse | 5 |
| Ovarian Neoplasms | 4 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 4 |
| Breast Neoplasms | 3 |
| Carcinoma, Ovarian Epithelial | 3 |
Trials
Showing 1 to 25 of 94. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.